Clinical Trial Applications in Greece: CTIS, Timelines and the FAST-EU Pilot

Since the transition period closed on 30 January 2025, every interventional clinical trial in the EU runs under Regulation (EU) No 536/2014 and the Clinical Trials Information System (CTIS). For sponsors planning studies in Greece, the practical questions are no longer about the new system itself, but about preparing a clean application, planning realistic timelines and knowing which national requirements still apply.

One portal, one dossier, national assessment

The Clinical Trials Regulation took effect on 31 January 2022, with a three-year transition for trials authorised under the old Directive. Trials that were still ongoing, or that were to be extended to another Member State, had to move into CTIS by the end of that period. In Greece, the Hellenic Medicines Organisation (EOF) states that initial applications and later amendments are submitted exclusively through CTIS. The Clinical Trials Department of EOF handles the assessment, and the National Ethics Committee is part of the national process.

Timelines: plan for the maximum, not the minimum

EMA guidance on transitioned trials notes that Member States may authorise within 60 days, or sooner, but that with requests for information (RFIs) the maximum is 106 days, and longer for some investigational products. Three practical consequences follow:

  • Clock-stops matter. Statutory holidays and the winter clock-stop can extend a submission made too close to the end of the year.
  • RFIs are the main schedule risk. A complete, consistent dossier at first submission is the best protection.
  • Mandatory fields must be completed. CTIS requires all mandatory fields and documents even where the old Directive did not.

Greek national points to check

  • Fees. EOF publishes a fee schedule under a Ministerial Decision, with separate amounts for approval and for modifications and reduced amounts for non-commercial studies. Confirm the current figures before budgeting.
  • Language. A 2022 joint ministerial decree amended the national rules on translating the protocol into Greek for CTIS-submitted trials. Check what applies to your study.
  • GCP inspections. EOF may inspect before, during or after a trial, and findings are answered with a CAPA plan before the final report.

FAST-EU: a faster route for multinational trials

FAST-EU is a joint pilot of the Heads of Medicines Agencies, the Clinical Trials Coordination Group and MedEthics EU. It is intended to speed up multinational trials by running validation, assessment and ethics opinions in parallel, with a maximum of 70 days from CTIS submission to final decision, including sponsor response times. According to the HPRA, the pilot started on 30 January 2026 and is expected to run for one year, and EOF has announced that it has joined. It operates fully within CTIS and the Regulation. Interested sponsors submit an expression of interest to the FAST-EU mailbox. Because the pilot is time-limited, any sponsor considering it should decide early.

How PQRA helps

PQRA supports sponsors and CROs with clinical trial regulatory strategy in Greece and the EU: CTIS dossier readiness reviews, coordination of Greek-language and national documents, RFI response planning, alignment with the wider regulatory and pharmacovigilance plan, and inspection preparation.

Planning a trial in Greece? Contact the PQRA team to discuss your application.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *